Global Newsroom | CSL

Published Large U.S. Study Finds Comparable Effectiveness Between Adjuvanted and High-Dose Influenza Vaccines in Adults 65 Years and Older

Large cluster-randomized crossover study involving nearly 430,000 U.S. adults aged 65 years and older was published in the Journal of the American Medical Association (JAMA) Network ...
Global Newsroom | CSL

CSL Seqirus Signs Long-Term Agreement with the Pan American Health Organization (PAHO) to Advance Pandemic Influenza Preparedness in Latin America and the Cari…

A new long-term pandemic preparedness agreement between CSL Seqirus and PAHO’s Regional Revolving Fund builds on the parties’ ...
newsroom.csl

Global Newsroom

Australia’s onshore vaccine manufacturing capabilities took a leap forward today as The Hon Mark Butler MP, Minister for Health, Disability and Ageing,... Melbourne, 16 February 2026 CSL Seqirus, part ...
newsroom.csl

CSL announces rise in full year net profit

MELBOURNE, Aug. 19, 2025 /PRNewswire/ -- Global biotherapeutics leader CSL today announced a reported net profit after tax of US$3.0 billion for the 12 months ended 30 June 2025, up 17% on a constant ...
newsroom.csl

U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once ...

ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacks Once-monthly dosing reduced HAE attacks by a median of more than 99 percent and a ...
newsroom.csl

Australia’s Therapeutic Goods Administration (TGA) Approves Registration of CSL’s ANDEMBRY® (garadacimab) for the Prevention of Recurrent Hereditary Angioedema (HAE) Attacks

Discovered and developed in Australia by CSL scientists, ANDEMBRY is CSL’s first monoclonal antibody treatment; reinforces company’s commitment to providing a wide range of treatment modalities to ...